Skip to main content
. 2023 Jul 3;15(13):3022. doi: 10.3390/nu15133022

Figure 3.

Figure 3

EGCG targets various pathways and metabolic processes to alleviate non-alcoholic fatty liver disease (NAFLD): SCFA: shorty chain fatty acids, ROS: reactive oxygen species, AST: aspartate aminotransferase, ALT: alanine aminotransaminase, NF-κB: nuclear factor kappa B, TLR 4: toll-like receptor 4.